| Name | Cvs Pharmacy#11082 |
|---|---|
| Organization Name | Cvs Pharmacy Inc |
| Location | 341 Harrison Ave, Boston, Massachusetts 02118 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (617) 556-3922 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Scientists from The Whitehead Institute used zinc finger nucleases (ZFNs) designed by Sangamo BioSciences, Inc., (Nasdaq: SGMO) to efficiently and precisely modify the genomes of human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs).
MSNBC's First Read reports that Senate Finance Committee Chairman Max Baucus released a statement earlier today saying that his panel "is still working on a bipartisan bill." According to MSNBC, Baucus said: "Bipartisan progress continues.
International Diabetes Federation Middle East and North Africa Region (MENA) today launched a diabetes action plan, marking a major step forward towards optimal disease management in type 2 diabetes. The MENA action plan aims to improve the prevention, treatment and care of diabetes, which has reached epidemic proportions in the region and has overtaken wider communicable diseases as a health risk.
BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research 2013 Annual Meeting.
› Verified 6 days ago
| NPI Number | 1457832933 |
| Organization Name | CVS PHARMACY INC |
| Doing Business As | CVS PHARMACY #11082 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 341 Harrison Ave, Boston, MA 02118 |
| Phone Number | 617-556-3922 |
News Archive
Scientists from The Whitehead Institute used zinc finger nucleases (ZFNs) designed by Sangamo BioSciences, Inc., (Nasdaq: SGMO) to efficiently and precisely modify the genomes of human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs).
MSNBC's First Read reports that Senate Finance Committee Chairman Max Baucus released a statement earlier today saying that his panel "is still working on a bipartisan bill." According to MSNBC, Baucus said: "Bipartisan progress continues.
International Diabetes Federation Middle East and North Africa Region (MENA) today launched a diabetes action plan, marking a major step forward towards optimal disease management in type 2 diabetes. The MENA action plan aims to improve the prevention, treatment and care of diabetes, which has reached epidemic proportions in the region and has overtaken wider communicable diseases as a health risk.
BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research 2013 Annual Meeting.
› Verified 6 days ago
News Archive
Scientists from The Whitehead Institute used zinc finger nucleases (ZFNs) designed by Sangamo BioSciences, Inc., (Nasdaq: SGMO) to efficiently and precisely modify the genomes of human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs).
MSNBC's First Read reports that Senate Finance Committee Chairman Max Baucus released a statement earlier today saying that his panel "is still working on a bipartisan bill." According to MSNBC, Baucus said: "Bipartisan progress continues.
International Diabetes Federation Middle East and North Africa Region (MENA) today launched a diabetes action plan, marking a major step forward towards optimal disease management in type 2 diabetes. The MENA action plan aims to improve the prevention, treatment and care of diabetes, which has reached epidemic proportions in the region and has overtaken wider communicable diseases as a health risk.
BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research 2013 Annual Meeting.
› Verified 6 days ago
Cvs Pharmacy #02971 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 350 Longwood Ave, Boston, Massachusetts 02115 Phone: (617) 731-8665 | |
Cvs Pharmacy #02516 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 35 Kneeland St, Boston, Massachusetts 02111 Phone: (617) 542-1885 | |
Cvs Pharmacy #11274 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 780 Albany St, Boston, Massachusetts 02118 Phone: (617) 638-0030 | |
Boston Medical Center Outpatient Pa Type: Community/Retail Pharmacy Location: 725 Albany St, Boston, Massachusetts 02118 Phone: (617) 414-4880 | |
Cvs Pharmacy #01258 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 191-193 Cambridge St, Boston, Massachusetts 02114 Phone: (617) 367-0441 |